{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:38:45Z","timestamp":1764733125650,"version":"3.40.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06312-2","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:09:52Z","timestamp":1742288992000},"page":"2545-2549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+\/FLT3-ITD\u2009+\u2009acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Kun","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"20","key":"6312_CR1","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood.2020007093","volume":"136","author":"NL Michmerhuizen","year":"2020","unstructured":"Michmerhuizen NL, Klco JM, Mullighan CG (2020) Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood 136(20):2275\u20132289. https:\/\/doi.org\/10.1182\/blood.2020007093","journal-title":"Blood"},{"issue":"13","key":"6312_CR2","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","volume":"118","author":"IH Hollink","year":"2011","unstructured":"Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM (2011) NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118(13):3645\u20133656. https:\/\/doi.org\/10.1182\/blood-2011-04-346643","journal-title":"Blood"},{"issue":"1","key":"6312_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr., Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S (2018) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24(1):103\u2013112. https:\/\/doi.org\/10.1038\/nm.4439","journal-title":"Nat Med"},{"key":"6312_CR4","doi-asserted-by":"publisher","unstructured":"Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, Waack K, Creutzig U, Hanenberg H, Reinhardt D (2019) Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol 2019(1609128). https:\/\/doi.org\/10.1155\/2019\/1609128","DOI":"10.1155\/2019\/1609128"},{"issue":"15","key":"6312_CR5","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","volume":"124","author":"F Ostronoff","year":"2014","unstructured":"Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S (2014) NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124(15):2400\u20132407. https:\/\/doi.org\/10.1182\/blood-2014-04-570929","journal-title":"Blood"},{"issue":"5","key":"6312_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12185-017-2395-x","volume":"107","author":"A Shimada","year":"2018","unstructured":"Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM, Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S (2018) Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol 107(5):586\u2013595. https:\/\/doi.org\/10.1007\/s12185-017-2395-x","journal-title":"Int J Hematol"},{"issue":"7248","key":"6312_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nature08036","volume":"459","author":"GG Wang","year":"2009","unstructured":"Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD (2009) Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459(7248):847\u2013851. https:\/\/doi.org\/10.1038\/nature08036","journal-title":"Nature"},{"issue":"4","key":"6312_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003267","volume":"136","author":"J Schmoellerl","year":"2020","unstructured":"Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F (2020) CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood 136(4):387\u2013400. https:\/\/doi.org\/10.1182\/blood.2019003267","journal-title":"Blood"},{"issue":"8","key":"6312_CR9","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","volume":"7","author":"M Rasouli","year":"2023","unstructured":"Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O (2023) The MLL-Menin interaction is a therapeutic vulnerability in NUP98-rearranged AML. Hemasphere 7(8):e935. https:\/\/doi.org\/10.1097\/HS9.0000000000000935","journal-title":"Hemasphere"},{"issue":"22","key":"6312_CR10","first-page":"6227","volume":"60","author":"HG Ahuja","year":"2000","unstructured":"Ahuja HG, Hong J, Aplan PD, Tcheurekdjian L, Forman SJ, Slovak ML (2000) t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res 60(22):6227\u20136229","journal-title":"Cancer Res"},{"issue":"3","key":"6312_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/gcc.10119","volume":"35","author":"C Panarello","year":"2002","unstructured":"Panarello C, Rosanda C, Morerio C (2002) Cryptic translocation t(5;11)(q35;p15.5) with involvement of the NSD1 and NUP98 genes without 5q deletion in childhood acute myeloid leukemia. Genes Chromosomes Cancer 35(3):277\u2013281. https:\/\/doi.org\/10.1002\/gcc.10119","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"6312_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cancergencyto.2009.03.007","volume":"193","author":"N Tosic","year":"2009","unstructured":"Tosic N, Stojiljkovic M, Colovic N, Colovic M, Pavlovic S (2009) Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review. Cancer Genet Cytogenet 193(2):98\u2013103. https:\/\/doi.org\/10.1016\/j.cancergencyto.2009.03.007","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"6312_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","volume":"51","author":"I Iacobucci","year":"2019","unstructured":"Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D\u2019Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG (2019) Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet 51(4):694\u2013704. https:\/\/doi.org\/10.1038\/s41588-019-0375-1","journal-title":"Nat Genet"},{"issue":"3","key":"6312_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/leu.2016.267","volume":"31","author":"S Struski","year":"2017","unstructured":"Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E (2017) NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 31(3):565\u2013572. https:\/\/doi.org\/10.1038\/leu.2016.267","journal-title":"Leukemia"},{"issue":"4","key":"6312_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/leu.2016.361","volume":"31","author":"V Bisio","year":"2017","unstructured":"Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, Masetti R, Togni M, Di Giacomo D, Minuzzo S, Leszl A, Zappavigna V, Rondelli R, Mecucci C, Pession A, Locatelli F, Basso G, Pigazzi M (2017) NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia 31(4):974\u2013977. https:\/\/doi.org\/10.1038\/leu.2016.361","journal-title":"Leukemia"},{"issue":"6","key":"6312_CR16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41375-018-0327-2","volume":"33","author":"JL Kivioja","year":"2019","unstructured":"Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, Heckman CA (2019) Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)\/FLT3-ITD(+) acute myeloid leukemia. Leukemia 33(6):1360\u20131372. https:\/\/doi.org\/10.1038\/s41375-018-0327-2","journal-title":"Leukemia"},{"issue":"2","key":"6312_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-022-05047-8","volume":"102","author":"H Sun","year":"2023","unstructured":"Sun H, Yan H, Yan Z, Zhu Y, Yang G, Zhang S (2023) Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT. Ann Hematol 102(2):473\u2013475. https:\/\/doi.org\/10.1007\/s00277-022-05047-8","journal-title":"Ann Hematol"},{"issue":"6","key":"6312_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ccell.2016.10.019","volume":"30","author":"H Xu","year":"2016","unstructured":"Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA (2016) NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis. Cancer Cell 30(6):863\u2013878. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.019","journal-title":"Cancer Cell"},{"issue":"6","key":"6312_CR19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","volume":"139","author":"EB Heikamp","year":"2022","unstructured":"Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, Kentsis A, Armstrong SA (2022) The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood 139(6):894\u2013906. https:\/\/doi.org\/10.1182\/blood.2021012806","journal-title":"Blood"},{"key":"6312_CR20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286537","author":"HE Carraway","year":"2024","unstructured":"Carraway HE, Nakitandwe J, Cacovean A, Ma Y, Munneke B, Waghmare G, Mandap C, Ahmed U, Kowalczyk N, Butler T, Morris SW (2024) Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent Menin inhibitor BMF-219, Icovamenib. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.286537","journal-title":"Haematologica"},{"issue":"7954","key":"6312_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Schaller D, Mowla S, Xiao W, Gamlen HA, Stonestrom AJ, Persaud S, Ener E, Cutler JA, Doench JG, McGeehan GM, Volkamer A, Chodera JD, Nowak RP, Fischer ES, Levine RL, Armstrong SA, Cai SF (2023) MEN1 mutations mediate clinical resistance to Menin Inhibition. Nature 615(7954):913\u2013919. https:\/\/doi.org\/10.1038\/s41586-023-05755-9","journal-title":"Nature"},{"issue":"2","key":"6312_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0092-8674(95)90331-3","volume":"81","author":"A Radu","year":"1995","unstructured":"Radu A, Moore MS, Blobel G (1995) The peptide repeat domain of nucleoporin Nup98 functions as a Docking site in transport across the nuclear pore complex. Cell 81(2):215\u2013222. https:\/\/doi.org\/10.1016\/0092-8674(95)90331-3","journal-title":"Cell"},{"issue":"11","key":"6312_CR23","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1091\/mbc.e09-12-1041","volume":"21","author":"M Oka","year":"2010","unstructured":"Oka M, Asally M, Yasuda Y, Ogawa Y, Tachibana T, Yoneda Y (2010) The mobile FG nucleoporin Nup98 is a cofactor for Crm1-dependent protein export. Mol Biol Cell 21(11):1885\u20131896. https:\/\/doi.org\/10.1091\/mbc.e09-12-1041","journal-title":"Mol Biol Cell"},{"key":"6312_CR24","doi-asserted-by":"publisher","unstructured":"Schmidt HB, Gorlich D (2015) Nup98 FG domains from diverse species spontaneously phase-separate into particles with nuclear pore-like permselectivity. Elife 4. https:\/\/doi.org\/10.7554\/eLife.04251","DOI":"10.7554\/eLife.04251"},{"issue":"21","key":"6312_CR25","doi-asserted-by":"publisher","first-page":"16248","DOI":"10.1074\/jbc.M109.048785","volume":"285","author":"A Takeda","year":"2010","unstructured":"Takeda A, Sarma NJ, Abdul-Nabi AM, Yaseen NR (2010) Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins. J Biol Chem 285(21):16248\u201316257. https:\/\/doi.org\/10.1074\/jbc.M109.048785","journal-title":"J Biol Chem"},{"key":"6312_CR26","doi-asserted-by":"publisher","first-page":"e09540","DOI":"10.7554\/eLife.09540","volume":"5","author":"M Oka","year":"2016","unstructured":"Oka M, Mura S, Yamada K, Sangel P, Hirata S, Maehara K, Kawakami K, Tachibana T, Ohkawa Y, Kimura H, Yoneda Y (2016) Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of hox cluster genes. Elife 5:e09540. https:\/\/doi.org\/10.7554\/eLife.09540","journal-title":"Elife"},{"issue":"12","key":"6312_CR27","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, Taub JW, Ge Y (2018) Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med 22(12):6099\u20136111. https:\/\/doi.org\/10.1111\/jcmm.13886","journal-title":"J Cell Mol Med"},{"issue":"17","key":"6312_CR28","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","volume":"125","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R (2015) Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor Selinexor in acute myeloid leukemia. Blood 125(17):2689\u20132692. https:\/\/doi.org\/10.1182\/blood-2014-10-607648","journal-title":"Blood"},{"issue":"1","key":"6312_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Azizian NG, Dou Y, Pham LV, Li Y (2019) Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol 12(1):119. https:\/\/doi.org\/10.1186\/s13045-019-0803-9","journal-title":"J Hematol Oncol"},{"issue":"4","key":"6312_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12185-019-02665-3","volume":"110","author":"Y Mitani","year":"2019","unstructured":"Mitani Y, Hiwatari M, Seki M, Hangai M, Takita J (2019) Successful treatment of acute myeloid leukemia co-expressing NUP98\/NSD1 and FLT3\/ITD with preemptive donor lymphocyte infusions. Int J Hematol 110(4):512\u2013516. https:\/\/doi.org\/10.1007\/s12185-019-02665-3","journal-title":"Int J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06312-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:14:07Z","timestamp":1746414847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6312"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06312-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Full written consent was obtained from the legal guardians of patient for the writing and publication of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}